SCHEMBL4893348

SCHEMBL4893348

Cc1ccc(C(N)=O)cc1Nc1nccc(-c2ccc(-n3ccnc3)cc2)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMKK2 Q96RR4 4/20 0.62
LCK P06239 4/20 0.52
IKBKB O14920 1/20 0.50
JAK2 O60674 1/20 0.49
MAPK8 P45983 2/20 0.49
ABL1 P00519 10/20 0.49
BCR P11274 5/20 0.49
PDGFRA P16234 8/20 0.48
PDGFRB P09619 8/20 0.48
KIT P10721 5/20 0.48
LYN P07948 3/20 0.48
FLT3 P36888 3/20 0.48
DDR2 Q16832 3/20 0.48
PIK3CG P48736 1/20 0.48
GSK3B P49841 1/20 0.48
MAPK10 P53779 1/20 0.47
EGFR P00533 1/20 0.47
PRKCA P17252 1/20 0.47
LDLR P01130 1/20 0.46
PCSK9 Q8NBP7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4893357 0.85 ABL1 (0.61) CAMKK2LCKIKBKBABL1BCR
SCHEMBL4899264 0.85 JAK2 (0.66) CAMKK2IKBKBJAK2MAPK8ABL1
SCHEMBL4901347 0.85 PDGFRA (0.69) LCKMAPK8ABL1BCRPDGFRA
SCHEMBL4904288 0.84 CAMKK2 (0.71) CAMKK2LCKMAPK8ABL1BCR
SCHEMBL4900996 0.83 PDGFRA (0.70) LCKMAPK8ABL1BCRPDGFRA
SCHEMBL4902199 0.83 ABL1 (0.63) CAMKK2IKBKBJAK2MAPK8ABL1
SCHEMBL4899621 0.81 PDGFRA (0.57) LCKABL1BCRPDGFRAPDGFRB
SCHEMBL4902240 0.81 ABL1 (0.71) LCKMAPK8ABL1BCRPDGFRA
SCHEMBL4903439 0.81 IKBKB (0.50) CAMKK2IKBKBABL1BCRPDGFRA
SCHEMBL4891653 0.81 PDGFRA (0.70) LCKABL1BCRPDGFRAPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US claimed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP claimed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO claimed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP disclosed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080187575-A1 Pyrimidine Derivatives TYMP, TDP1, PNP CAMKK2 4550/4885LCK 328/4885IKBKB 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.